Crispr Therapeutics AG (CRSP) stock has risen 22.24% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 62 out of a possible 100.

That rank is chiefly influenced by a short-term technical score of 76. CRSP's rank also includes a fundamental score of 55. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 72. This means analysts expect the stock to increase 46.22% over the next 12 months. The long-term technical score for CRSP is 54.

Overall Score - 62
CRSP has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on CRSP!

What's Happening with CRSP Stock Today

Crispr Therapeutics AG (CRSP) stock is higher by 0.09% while the S&P 500 is unchanged 0% as of 11:20 AM on Friday, May 1. CRSP has risen $0.04 from the previous closing price of $49.20 on volume of 326,369 shares. Over the past year the S&P 500 is lower by -0.17% while CRSP has risen 22.24%. CRSP earned $0.75 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 65.84.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Source link